ovarian cancer
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
October 29, 2025Pharma&, Rubraca, Scottish Medicines Consortium, nhs scotland, oncology, ovarian cancer
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by the Scottish Medicines Consortium (SMC) …
Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint
April 1, 2025Research and Development Corcept Therapeutics, Oncology, ovarian cancer, research and development
Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase …
TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment
April 10, 2024Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer
TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …
J&J’s appeal shot down over $2.12m payment due to allegedly carcinogenic talc products
November 4, 2020Research and Development, Sales and Marketing J&J, JJ, baby powder, ovarian cancer, talc
Johnson & Johnson has suffered a legal defeat in its ongoing dispute with consumers over damages relating to use of …
Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer
July 13, 2020Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq
Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …
Lynparza combo authorised in US for first-line maintenance of HRD-positive advanced ovarian cancer
May 11, 2020Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer
Lynparza (olaparib), developed by AstraZeneca and MSD, has secured FDA approval when paired with bevacizumab as a first-line maintenance treatment …
Women who take statins could be less likely to develop ovarian cancer, study finds
February 19, 2020Research and Development, Sales and Marketing Cancer, Cancer Research UK, cholesterol, ovarian cancer, statins
A study by Cancer Research UK has found that women who take statins, drugs that lower cholesterol, are less likely …
Jury orders Johnson & Johnson to pay $750 million in latest baby powder case
February 7, 2020Medical Communications J&J, JJ, Johnson & Johnson, ovarian cancer, talc, talc powder
Johnson & Johnson have been ordered to pay by a jury $750 million to four plaintiffs over the company’s baby …
NICE authorises Lynparza for NHS use in all BRCA-mutated ovarian cancer cases
December 2, 2019Sales and Marketing Cancer, NHS, NICE, lynparza, ovarian cancer, pharma
NICE has given its recommendation for the routine use on the NHS in England and Wales of AstraZeneca and MSD’s …
Ovarian cancer market set to smash $6.7 billion by 2025
October 28, 2019Sales and Marketing Cancer, GlobalData, ovarian cancer, pharma
New research from GlobalData has forecast that the worldwide market for ovarian cancer is set to expand at a compound …
Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer
October 11, 2019Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma
NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …
GSK’s Zejula slows disease progression in a range of ovarian cancers
October 2, 2019Research and Development Cancer, ESMO 2019, GSK, Zejula, ovarian cancer, pharma
At the 2019 European Society for Medical Oncology (ESMO) congress, GlaxoSmithKline unveiled new Phase 3 data on Zejula (niraparib) for …
Lynparza extends progression-free survival in first-line advanced ovarian cancer, with or without BRCA mutations
August 14, 2019Research and Development AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
New Phase 3 data has emerged on AstraZeneca and MSD’s Lynparza (olaparib), showing that the PARP inhibitor achieved its primary …
EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer
June 18, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …
ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial
May 16, 2019Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …
